drugset / Trial / NCT01582451

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus

NCT01582451 ↗

Phase 3 Completed 466 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks: * Change in participants' overall blood sugar control * The rate of night time low blood sugar episodes * The number of participants that reach blood sugar targets without low blood sugar episodes at night * The rate of low blood sugar episodes reported over a 24-hour period

Timeline

Start
2012-05
Primary completion
2013-05
Completion
2013-12

Outcome

Met primary endpoint

paper At 26 weeks, reduction in HbA1c was superior with BIL versus glargine (-0.82% [-8.9 mmol/mol] vs. -0.29% [-3.2 mmol/mol]; PMID 26577417 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Peglispro Protein / enzyme biologic — Subcutaneous
Comparator insulin glargine Protein / enzyme biologic — Subcutaneous